Unique ID issued by UMIN | UMIN000004349 |
---|---|
Receipt number | R000004710 |
Scientific Title | PhaseI/II study of Docetaxel/S-1 with radiation for unresectable and/or recurrent esophageal cancer |
Date of disclosure of the study information | 2010/11/01 |
Last modified on | 2013/10/23 12:22:04 |
PhaseI/II study of Docetaxel/S-1 with radiation for unresectable and/or recurrent esophageal cancer
SP vs DS
PhaseI/II study of Docetaxel/S-1 with radiation for unresectable and/or recurrent esophageal cancer
SP vs DS
Japan |
unresectyable esophageal cancer,
recurrent esophageal cancer
Gastrointestinal surgery |
Malignancy
NO
To clarify the efficacy and the safety of this regimen for unresectable esophageal cancer patient without distant metastasis and recurrent esophageal cancer patient, using the dosage determined by previous phase I study.
Safety,Efficacy
Confirmatory
Pragmatic
Phase I,II
overall response
Overall suevivalsurvival
Time to progression
toxicity
Local conterol rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Patients were given S-1 (60mg/m2/day) orally from days 1 to 14, and Docetaxel (20 mg/m2 ) intravenously on days 1 and 8. Patients received radiation in 2.0 Gy daily fractions from days 1 to 21, for a total of 30 Gy. Patients were given a seven-day rest after the first course, and then treated with the same regimen from days 28 to 49.
18 | years-old | <= |
80 | years-old | > |
Male and Female
1.The patients must have histologically proven squamous cell carcinoma of the esophagus.
2.The tumor is T4 and/or M1 LYM without other organ metastasis or recurrent cancer.
3.The tumor has a measurable lesion for evaluation.
4.No previous treatment or more 4 weeks passed before previous treatment
5.All areas of the disease can be encompassed in the radiation port.
6.The patient's performance status is 0 to 1.
7.The patient's age is 18- 80 years.
8. Adequate organ function
9.WBC count is 4,000/mm3 or more and neutrophil count is 2000 /mm3 or more
Platelet count is 100,000/mm3 or more
Hemoglobin is 9.5 g/dl or more
AST and ALT levels are within twice the normal upper limits
Serum bilirubin level is 1.5 mg/dl or less
Serum creatinin levels are 1.5 mg/dl or less
10.Life expectancy expectd more than 12 weeks
11. Written informed consent
Excluded criteria is follow;
1.the case complicated severe heart failure,liver chirrhosis, uncontrolled diabets, interstitial pneumonia or fibriod lung, pooling of pleural effusion needed treatment and pericardial effusion.
2.the case suspected of infection with feaveer
3.the case had the motion disturbance, peripheral nerve palsy and severe edema
4.the case complicated other active cancer
5.pregnant woman or lactational woman
30
1st name | |
Middle name | |
Last name | Toshihiro Hirai |
Kawasaki Medical University
Department of Digestive Surgery
Matsushima 577, Kurashi City, Okayama
086-462-1111
1st name | |
Middle name | |
Last name | Hideo Matsumoto |
Kawasaki Medical University
Department of Digestive Surgery
Matsushima 577, Kurashi City, Okayama
086-462-1111
h-mastu@med.kawasaki-m.ac.jp
Department of Digestive surgery,
Kawasaki Medical University
not existed
Self funding
NO
川崎医科大学附属病院
2010 | Year | 11 | Month | 01 | Day |
Partially published
Completed
2006 | Year | 03 | Month | 31 | Day |
2010 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2015 | Year | 12 | Month | 01 | Day |
2010 | Year | 10 | Month | 07 | Day |
2013 | Year | 10 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004710
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |